Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

54.50 -0.95 (-1.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,002,569
Open 54.37
Bid (Size) 52.69 (1)
Ask (Size) 55.15 (1)
Prev. Close 55.45
Today's Range 53.98 - 54.84
52wk Range 45.22 - 60.12
Shares Outstanding 1,250,690,553
Dividend Yield 3.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Don't overlook SANOFI-ADR (NASDAQ:SNY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Discover SANOFI-ADR, an undervalued stock. NASDAQ:SNY showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga

Performance

YTD
+13.1%
+13.1%
1 Month
+1.4%
+1.4%
3 Month
+12.5%
+12.5%
6 Month
-3.8%
-3.8%
1 Year
+9.5%
+9.5%

More News

Read More
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Via Benzinga
Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal
Via Benzinga
Is NASDAQ:SNY suited for dividend investing?
Via Chartmill
How Is The Market Feeling About Sanofi?
Via Benzinga
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics.
Via Chartmill
FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
Via Benzinga
Exposures Product Safety
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Via Benzinga
Exposures Product Safety
Merck Injects $1 Billion To Expand Vaccine Production In US
Via Benzinga
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
Via Benzinga
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Via Benzinga
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients
Via Benzinga
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Via Benzinga
For those who appreciate value investing, SANOFI-ADR (NASDAQ:SNY) is a compelling option with its solid fundamentals.
Via Chartmill
Is SANOFI-ADR (NASDAQ:SNY) Ready to Break Out of Its Range?
Via Chartmill
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership
Via Stocktwits
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Via Investor's Business Daily
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Via Benzinga
Exposures COVID-19
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
Via MarketBeat
Exposures Product Safety
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples
Via Stocktwits
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Via Benzinga
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Via Benzinga
Exposures Product Safety

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 54.50
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 03/26/25 04:00 PM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 68.16B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 68B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.